Cargando…
Activation of cGMP/PKG/p65 signaling associated with PDE5‐Is downregulates CCL5 secretion by CD8 (+) T cells in benign prostatic hyperplasia
BACKGROUND: Benign prostatic hyperplasia (BPH) is the most common urological disease in elderly men, but the underlying pathophysiological mechanisms are complex and not fully understood. Phosphodiesterase type 5 inhibitors (PDE5‐Is) used to treat BPH could upregulate the cyclic guanosine monophosph...
Autores principales: | Jin, Song, Xiang, Peng, Liu, Jie, Yang, Yang, Hu, Shuai, Sheng, Jindong, He, Qun, Yu, Wei, Han, Wenke, Jin, Jie, Peng, Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593656/ https://www.ncbi.nlm.nih.gov/pubmed/30958912 http://dx.doi.org/10.1002/pros.23801 |
Ejemplares similares
-
The NO/cGMP/PKG pathway in platelets: The therapeutic potential of PDE5 inhibitors in platelet disorders
por: Degjoni, Anisa, et al.
Publicado: (2022) -
PDE5 says NO to cGMP
por: LeBrasseur, Nicole
Publicado: (2003) -
Burn-Induced Cardiac Mitochondrial Dysfunction via Interruption of the PDE5A-cGMP-PKG Pathway
por: Wen, Jake J., et al.
Publicado: (2020) -
The role of cGMP and PKG in cardioprotection
por: Downey, James M, et al.
Publicado: (2009) -
Myostatin Mutation Promotes Glycolysis by Increasing Phosphorylation of Phosphofructokinase via Activation of PDE5A-cGMP-PKG in Cattle Heart
por: Gu, Mingjuan, et al.
Publicado: (2022)